Evidence map›Paper›PMID 28631141›Full record

ArticleMolecular imaging and biology2018

Cell Labeling with Magneto-Endosymbionts and the Dissection of the Subcellular Location, Fate, and Host Cell Interactions.

Kayla R Lee, Abdul Wakeel, Papia Chakraborty, Chandler S Foote, Lauren Kajiura, Joyce C Barrozo, Andrea C Chan, Alexey V Bazarov, Ryan Spitler, Peter M Kutny and 7 more

Open access · greenAbstract read
In one paragraph

Article in Molecular imaging and biology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 1 country.

Kayla R LeeBell Biosystems, San Francisco, CA, USA.
Abdul WakeelBell Biosystems, San Francisco, CA, USA.
Papia ChakrabortyBell Biosystems, San Francisco, CA, USA.
Chandler S FooteBell Biosystems, San Francisco, CA, USA.
Lauren KajiuraBell Biosystems, San Francisco, CA, USA.
Joyce C BarrozoBell Biosystems, San Francisco, CA, USA.
Andrea C ChanBell Biosystems, San Francisco, CA, USA.
Alexey V BazarovBell Biosystems, San Francisco, CA, USA.
Ryan SpitlerPediatrics-Neonatology and Molecular Imaging Program (MIPS), Stanford University, Palo Alto, CA, USA.
Peter M KutnyMicroinjection Service, Genetic Engineering Technologies, The Jackson Laboratory, Bar Harbor, ME, USA.
Jim M DenegreThe Jackson Laboratory, Bar Harbor, ME, USA.
Rob A TaftDivision of Reproductive Technologies, The Jackson Laboratory, Bar Harbor, ME, USA.
Joachim SeemannDepartment of Cell Biology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Bradley W RiceBell Biosystems, San Francisco, CA, USA.
Christopher H ContagPediatrics-Neonatology and Molecular Imaging Program (MIPS), Stanford University, Palo Alto, CA, USA.
Brian K RuttRadiology Department and Molecular Imaging Program (MIPS), Stanford University, Palo Alto, CA, USA.
Caleb B BellBell Biosystems, San Francisco, CA, USA. caleb@bellbiosystems.com.
Bell Biosystems (United States) · USJackson Laboratory · USStanford University · USThe University of Texas Southwestern Medical Center · US

Funding

STANFORD CANCER IMAGING TRAINING (SCIT) PROGRAMT32CA009695 · NCI · STANFORD UNIVERSITY · PI BRUCE L DANIEL, Jeremy Dahl · 1993 to 2026
$7.7M
CELL CYCLE REGULATION OF GOLGI MEMBRANE DYNAMICSR01GM096070 · NIGMS · UT SOUTHWESTERN MEDICAL CENTER · PI SEEMANN, JOACHIM · 2011 to 2019
$3.0M
Pre-clinical quantitation of ovarian cancer tumor burden using Magnetic Particle Imaging and non-dilutive cell labelingR01EB019458 · NIBIB · UNIVERSITY OF CALIFORNIA BERKELEY · PI BELL, CALEB B., CONOLLY, STEVEN M · 2015 to 2018
$1.9M
Tracking cardiac engraftment and viability of MiPSC by MRIR44EB019239 · NIBIB · BELL BIOSYSTEMS, INC. · PI BELL, CALEB B., SVENDSEN, CLIVE NIELS · 2016 to 2017
$1.5M
Next Generation 7T MRI Platform Upgrade with Parallel Transmit CapabilitiesS10RR026351 · NCRR · STANFORD UNIVERSITY · PI RUTT, BRIAN KEITH · 2011 to 2011
$600k
Tracking cardiac engraftment and viability of MiPSC by MRIR43EB019239 · NIBIB · BELL BIOSYSTEMS, INC. · PI BAZAROV, ALEXEY, BELL, CALEB B. · 2014 to 2014
$225k
Single Cell Spatiotemporal and Functional Reporting using Magneto-EndosymbiontsR43TR001202 · NCATS · BELL BIOSYSTEMS, INC. · PI BELL, CALEB B., RUTT, BRIAN KEITH · 2015 to 2015
$225k
NCATS NIH HHS R43 TR001202NCATS NIH HHS R43TR001202NCI NIH HHS T32 CA 009695NCI NIH HHS T32 CA009695NCRR NIH HHS S10 RR026351NIBIB NIH HHS R01 EB019458NIBIB NIH HHS R43 EB019239NIBIB NIH HHS R43EB019239NIBIB NIH HHS R44 EB019239NIGMS NIH HHS R01 GM096070
6 · The paper itself

Abstract

purposeThe purposes of this study are to characterize magneto-endosymbiont (ME) labeling of mammalian cells and to discern the subcellular fate of these living contrast agents. MEs are novel magnetic resonance imaging (MRI) contrast agents that are being used for cell tracking studies. Understanding the fate of MEs in host cells is valuable for designing in vivo cell tracking experiments. PROCEDURES: The ME's surface epitopes, contrast-producing paramagnetic magnetosomal iron, and genome were studied using immunocytochemistry (ICC), Fe and MRI contrast measurements, and quantitative polymerase chain reaction (qPCR), respectively. These assays, coupled with other common assays, enabled validation of ME cell labeling and dissection of ME subcellular processing.

resultsThe assays mentioned above provide qualitative and quantitative assessments of cell labeling, the subcellular localization and the fate of MEs. ICC results, with an ME-specific antibody, qualitatively shows homogenous labeling with MEs. The ferrozine assay shows that MEs have an average of 7 fg Fe/ME, ∼30 % of which contributes to MRI contrast and ME-labeled MDA-MB-231 (MDA-231) cells generally have 2.4 pg Fe/cell, implying ∼350 MEs/cell. Adjusting the concentration of Fe in the ME growth media reduces the concentration of non-MRI contrast-producing Fe. Results from the qPCR assay, which quantifies ME genomes in labeled cells, shows that processing of MEs begins within 24 h in MDA-231 cells. ICC results suggest this intracellular digestion of MEs occurs by the lysosomal degradation pathway. MEs coated with listeriolysin O (LLO) are able to escape the primary phagosome, but subsequently co-localize with LC3, an autophagy-associated molecule, and are processed for digestion. In embryos, where autophagy is transiently suppressed, MEs show an increased capacity for survival and even replication. Finally, transmission electron microscopy (TEM) of ME-labeled MDA-231 cells confirms that the magnetosomes (the MRI contrast-producing particles) remain intact and enable in vivo cell tracking.

conclusionsMEs are used to label mammalian cells for the purpose of cell tracking in vivo, with MRI. Various assays described herein (ICC, ferrozine, and qPCR) allow qualitative and quantitative assessments of labeling efficiency and provide a detailed understanding of subcellular processing of MEs. In some cell types, MEs are digested, but the MRI-producing particles remain. Coating with LLO allows MEs to escape the primary phagosome, enhances retention slightly, and confirms that MEs are ultimately processed by autophagy. Numerous intracellular bacteria and all endosymbiotically derived organelles have evolved molecular mechanisms to avoid intracellular clearance, and identification of the specific processes involved in ME clearance provides a framework on which to develop MEs with enhanced retention in mammalian cells.

Indexed as

Cell CommunicationCell TrackingStaining and LabelingSymbiosisAnimalsAutophagyCell Line, TumorContrast MediaFerrozineHumansIronMagnetite NanoparticlesMice, Inbred BALB CRatsReproducibility of ResultsSubcellular FractionsContrast MediaFerrozineIronMagnetite NanoparticlesAutophagyCell trackingEndosymbiosisMagnetic resonance imaging (MRI)Magnetotactic bacteria

Identifiers

PMID28631141
PMCPMC5736464
OpenAlexW2667214715

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.